(Q37477141)

English

The monobactams

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

20 August 2017

1 reference

Europe PubMed Central

The monobactams (English)

1 reference

Europe PubMed Central

PubMed publication ID

20 August 2017

author name string

N S Brewer

1

1 reference

Europe PubMed Central

PubMed publication ID

20 August 2017

W C Hellinger

2

1 reference

Europe PubMed Central

PubMed publication ID

20 August 2017

language of work or name

0 references

publication date

1 November 1991

1 reference

Europe PubMed Central

PubMed publication ID

20 August 2017

1 reference

Europe PubMed Central

PubMed publication ID

20 August 2017

66

1 reference

Europe PubMed Central

PubMed publication ID

20 August 2017

11

1 reference

Europe PubMed Central

PubMed publication ID

20 August 2017

1152-1157

1 reference

Europe PubMed Central

PubMed publication ID

20 August 2017

Aztreonam: the first monobactam

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965797-8

7 January 2021

Activities of beta-lactam antibiotics against Escherichia coli strains producing extended-spectrum beta-lactamases

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965797-8

7 January 2021

Penetration of monobactam antibiotics (aztreonam, carumonam) into human prostatic tissue

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965797-8

7 January 2021

Multiple intravenous dose pharmacokinetic study of carumonam in healthy subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965797-8

7 January 2021

Bactericidal Activity of Tigemonam, Alone and in Combination with Gentamicin.

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965797-8

7 January 2021

Antibacterial Activity In Vitro of Tigemonam, a New Oral Monobactam.

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965797-8

7 January 2021

Involvement of penicillin-binding protein 2 with other penicillin-binding proteins in lysis of Escherichia coli by some beta-lactam antibiotics alone and in synergistic lytic effect of amdinocillin (mecillinam).

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965797-8

7 January 2021

Structure activity relationships among the monobactams

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965797-8

7 January 2021

In vitro activity and beta-lactamase stability of a monobactam, SQ 26,917, compared with those of aztreonam and other agents

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965797-8

7 January 2021

SQ 26,776: in-vitro antibacterial activity and susceptibility to beta-lactamases.

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965797-8

7 January 2021

Azthreonam (SQ 26,776), a synthetic monobactam specifically active against aerobic gram-negative bacteria

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965797-8

7 January 2021

In-vitro activity of SQ 26,776 against multiply-resistant enterobacteria--preliminary results

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965797-8

7 January 2021

Aztreonam: antibacterial activity, beta-lactamase stability, and interpretive standards and quality control guidelines for disk-diffusion susceptibility tests.

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965797-8

7 January 2021

Comparative in vitro study of SQ26,776.

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965797-8

7 January 2021

In-vitro activity of the monobactam, SQ 26,776, against Gram-negative bacteria and its stability to their beta-lactamases.

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965797-8

7 January 2021

In vitro antimicrobial activity of aztreonam alone and in combination against bacterial isolates from pediatric patients

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965797-8

7 January 2021

In vitro activity of aztreonam in combination with newer beta-lactams and amikacin against multiply resistant gram-negative bacilli

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965797-8

7 January 2021

In vitro activities of aztreonam, piperacillin, and ticarcillin combined with amikacin against amikacin-resistant Pseudomonas aeruginosa and P. cepacia isolates from children with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965797-8

7 January 2021

Serum bactericidal activity of aztreonam, cefoperazone, and amikacin, alone or in combination, against Escherichia coli, Klebsiella pneumoniae, Serratia marcescens, and Pseudomonas aeruginosa

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965797-8

7 January 2021

Pharmacology of aztreonam after intravenous infusion

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965797-8

7 January 2021

Metabolism and pharmacokinetics of aztreonam in healthy subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965797-8

7 January 2021

Biliary excretion of aztreonam in patients with biliary tract disease

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965797-8

7 January 2021

Pharmacokinetics of aztreonam in patients with various degrees of renal dysfunction

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965797-8

7 January 2021

Effect of hemodialysis and peritoneal dialysis on aztreonam pharmacokinetics.

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965797-8

7 January 2021

Penetration of aztreonam into cerebrospinal fluid of patients with and without inflamed meninges

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965797-8

7 January 2021

Penetration of aztreonam into cerebrospinal fluid of patients with bacterial meningitis

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965797-8

7 January 2021

Evaluation of aztreonam in difficult-to-treat infections with prolonged posttreatment follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965797-8

7 January 2021

Treatment of serious gram-negative infections with aztreonam

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965797-8

7 January 2021

Aztreonam in the treatment of urinary tract infection.

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965797-8

7 January 2021

Treatment of acute pelvic inflammatory disease with aztreonam, a new monocyclic beta-lactam antibiotic, and clindamycin

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965797-8

7 January 2021

Aztreonam plus clindamycin as therapy for pelvic infections in women

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965797-8

7 January 2021

Evaluation of aztreonam in the treatment of spontaneous bacterial peritonitis in patients with cirrhosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965797-8

7 January 2021

Pharmacokinetics of once daily intra-peritoneal aztreonam and vancomycin in the treatment of CAPD peritonitis

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965797-8

7 January 2021

Surgically treated gangrenous or perforated appendicitis. A comparison of aztreonam and clindamycin versus gentamicin and clindamycin

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965797-8

7 January 2021

Aztreonam plus clindamycin vs. tobramycin plus clindamycin for the treatment of intraabdominal infections

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965797-8

7 January 2021

Aztreonam in the treatment of bone and joint infections caused by gram-negative bacilli

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965797-8

7 January 2021

Aztreonam in the treatment of serious orthopedic infections

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965797-8

7 January 2021

Aztreonam treatment of gram-negative septicemia

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965797-8

7 January 2021

Clinical experience with aztreonam in the treatment of gram-negative bacteremia.

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965797-8

7 January 2021

Aztreonam therapy in neutropenic patients with cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965797-8

7 January 2021

Efficacy and safety of aztreonam-clindamycin versus tobramycin-clindamycin in the treatment of lower respiratory tract infections caused by aerobic gram-negative bacilli

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965797-8

7 January 2021

Treatment with aztreonam or tobramycin in critical care patients with nosocomial gram-negative pneumonia

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965797-8

7 January 2021

Safety profile of aztreonam in clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965797-8

7 January 2021

Lack of cross-reactivity between aztreonam , a monobactam antibiotic, and penicillin in penicillin-allergic subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965797-8

7 January 2021

Immediate hypersensitivity reactions to beta-lactam antibiotics

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965797-8

7 January 2021

Immediate hypersensitivity to aztreonam

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965797-8

7 January 2021

Immediate hypersensitivity to aztreonam and imipenem

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965797-8

7 January 2021

Aztreonam therapy for complicated urinary tract infections caused by multidrug-resistant bacteria

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965797-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of aztreonam and tobramycin in the treatment of lower respiratory tract infections caused by gram-negative bacilli

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2965797-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0025-6196(12)65797-8

1 reference

Europe PubMed Central

PubMed publication ID

20 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

20 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37477141&oldid=1707319258"